Design and application of oncolytic HSV vectors for glioblastoma therapy

References

• Louis DN, Ohgaki H, Wiestler OD et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol.114(2), 97–109 (2007).
   PubMed Web of Science ®Google Scholar
• McLendon RE, Halperin EC. Is the long-term survival of patients with intracranial glioblastoma multiforme overstated? Cancer98(8), 1745–1748 (2003).
   PubMed Web of Science ®Google Scholar
• Davis FG, Freels S, Grutsch J, Barlas S, Brem S. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973–1991. J. Neurosurg.88(1), 1–10 (1998).
   PubMed Web of Science ®Google Scholar
• Trouillas P, Menaud G, De Thé G, Aimard G, Devic M. [Epidemiological study of primary tumors of the neuraxis in the Rhone-Alps region. Quantitative data on the etiology and geographical distribution of 1670 tumors]. Rev. Neurol. (Paris)131(10), 691–708 (1975).
   PubMed Web of Science ®Google Scholar
• Soffer D, Gomori JM, Pomeranz S, Siegal T. Gliomas following low-dose irradiation to the head report of three cases. J. Neurooncol.8(1), 67–72 (1990).
   PubMed Web of Science ®Google Scholar
• Li FP, Fraumeni JF Jr. Prospective study of a family cancer syndrome. JAMA247(19), 2692–2694 (1982).
   PubMed Web of Science ®Google Scholar
• Reifenberger G, Collins VP. Pathology and molecular genetics of astrocytic gliomas. J. Mol. Med.82(10), 656–670 (2004).
   PubMed Web of Science ®Google Scholar
• Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am. J. Pathol.170(5), 1445–1453 (2007).
   PubMed Web of Science ®Google Scholar
• Gregory RI, Shiekhattar R. MicroRNA biogenesis and cancer. Cancer Res.65(9), 3509–3512 (2005).
   PubMed Web of Science ®Google Scholar
• He L, Thomson JM, Hemann MT et al. A microRNA polycistron as a potential human oncogene. Nature435(7043), 828–833 (2005).
   PubMed Web of Science ®Google Scholar
• Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res.65(14), 6029–6033 (2005).
   PubMed Web of Science ®Google Scholar
• Godlewski J, Nowicki MO, Bronisz A et al. Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res.68(22), 9125–9130 (2008).
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chao T, Li R et al. MicroRNA-128 inhibits glioma cells proliferation by targeting transcription factor E2F3a. J. Mol. Med.87(1), 43–51 (2009).
   PubMed Web of Science ®Google Scholar
• Ciafre SA, Galardi S, Mangiola A et al. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem. Biophys. Res. Commun.334(4), 1351–1358 (2005).
   PubMed Web of Science ®Google Scholar
• Holland EC, Li Y, Celestino J et al. Astrocytes give rise to oligodendrogliomas and astrocytomas after gene transfer of polyoma virus middle T antigen in vivo. Am. J. Pathol.157(3), 1031–1037 (2000).
   PubMed Web of Science ®Google Scholar
• Sanai N, Alvarez-Buylla A, Berger MS. Neural stem cells and the origin of gliomas. N. Engl. J. Med.353(8), 811–822 (2005).
   PubMed Web of Science ®Google Scholar
• Singh SK, Clarke ID, Terasaki M et al. Identification of a cancer stem cell in human brain tumors. Cancer Res.63(18), 5821–5828 (2003).
   PubMed Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med.285(21), 1182–1186 (1971).
   PubMed Web of Science ®Google Scholar
• Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat. Rev. Neurosci.8(8), 610–622 (2007).
   PubMed Web of Science ®Google Scholar
• Hoelzinger DB, Demuth T, Berens ME. Autocrine factors that sustain glioma invasion and paracrine biology in the brain microenvironment. J. Natl Cancer Inst.99(21), 1583–1593 (2007).
   PubMed Web of Science ®Google Scholar
• Ammirati M, Vick N, Liao YL, Ciric I, Mikhael M. Effect of the extent of surgical resection on survival and quality of life in patients with supratentorial glioblastomas and anaplastic astrocytomas. Neurosurgery21(2), 201–206 (1987).
   PubMed Web of Science ®Google Scholar
• Walker MD, Green SB, Byar DP et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N. Engl. J. Med.303(23), 1323–1329 (1980).
   PubMed Web of Science ®Google Scholar
• Loeffler JS, Alexander E 3rd, Wen PY et al. Results of stereotactic brachytherapy used in the initial management of patients with glioblastoma. J. Natl Cancer Inst.82(24), 1918–1921 (1990).
   PubMedGoogle Scholar
• Nieder C, Astner ST, Mehta MP, Grosu AL, Molls M. Improvement, clinical course, and quality of life after palliative radiotherapy for recurrent glioblastoma. Am. J. Clin. Oncol.31(3), 300–305 (2008).
   PubMed Web of Science ®Google Scholar
• Wilson CB, Boldrey EB, Enot KJ. 1,3-bis (2-chloroethyl)-1-nitrosourea (NSC-409962) in the treatment of brain tumors. Cancer Chemother. Rep.54(4), 273–281 (1970).
   PubMedGoogle Scholar
• Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin. Cancer Res.6(7), 2585–2597 (2000).
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med.352(10), 987–996 (2005).
   PubMed Web of Science ®Google Scholar
• Grothey A, Ellis LM. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies. Cancer J.14(3), 170–177 (2008).
   PubMed Web of Science ®Google Scholar
• Dario A, Tomei G. The safety of the temozolomide in patients with malignant glioma. Curr. Drug Saf.1(2), 205–222 (2006).
   PubMedGoogle Scholar
• Roodhart JM, Langenberg MH, Witteveen E, Voest EE. The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. Curr. Clin. Pharmacol.3(2), 132–143 (2008).
   PubMedGoogle Scholar
• Curran WJ Jr, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J. Natl Cancer Inst.85(9), 704–710 (1993).
   PubMed Web of Science ®Google Scholar
• Salcman M. Survival in glioblastoma: historical perspective. Neurosurgery7(5), 435–439 (1980).
   PubMed Web of Science ®Google Scholar
• Lu C, Shervington A. Chemoresistance in gliomas. Mol. Cell. Biochem.312(1–2), 71–80 (2008).
   PubMed Web of Science ®Google Scholar
• Frampton AR Jr, Goins WF, Nakano K, Burton EA, Glorioso JC. HSV trafficking and development of gene therapy vectors with applications in the nervous system. Gene Ther.12(11), 891–901 (2005).
   PubMed Web of Science ®Google Scholar
• Aghi M, Visted T, Depinho RA, Chiocca EA. Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16. Oncogene27(30), 4249–4254 (2008).
   PubMed Web of Science ®Google Scholar
• Goldstein JN, Weller SK. In vitro processing of herpes simplex virus type 1 DNA replication intermediates by the viral alkaline nuclease, UL12. J. Virol.72(11), 8772–8781 (1998).
   PubMed Web of Science ®Google Scholar
• Fulci G, Dmitrieva N, Gianni D et al. Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses. Cancer Res.67(19), 9398–9406 (2007).
   PubMed Web of Science ®Google Scholar
• Fulci G, Chiocca EA. The status of gene therapy for brain tumors. Expert Opin. Biol. Ther.7(2), 197–208 (2007).
   PubMed Web of Science ®Google Scholar
• Chambers R, Gillespie GY, Soroceanu L et al. Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a SCID mouse model of human malignant glioma. Proc. Natl Acad. Sci. USA92(5), 1411–1415 (1995).
   PubMed Web of Science ®Google Scholar
• Bradley JD, Kataoka Y, Advani S et al. Ionizing radiation improves survival in mice bearing intracranial high-grade gliomas injected with genetically modified herpes simplex virus. Clin. Cancer Res.5(6), 1517–1522 (1999).
   PubMed Web of Science ®Google Scholar
• Bennett JJ, Adusumilli P, Petrowsky H et al. Up-regulation of GADD34 mediates the synergistic anticancer activity of mitomycin C and a γ134.5 deleted oncolytic herpes virus (G207). FASEB J.18(9), 1001–1003 (2004).
   PubMed Web of Science ®Google Scholar
• Dempsey MF, Wyper D, Owens J et al. Assessment of 123I-FIAU imaging of herpes simplex viral gene expression in the treatment of glioma. Nucl. Med. Commun.27(8), 611–617 (2006).
   PubMed Web of Science ®Google Scholar
• Detta A, Harland J, Hanif I, Brown SM, Cruickshank G. Proliferative activity and in vitro replication of HSV1716 in human metastatic brain tumours. J. Gene Med.5(8), 681–689 (2003).
   PubMed Web of Science ®Google Scholar
• Quigg M, Mairs RJ, Brown SM et al. Assessment in vitro of a novel therapeutic strategy for glioma, combining herpes simplex virus HSV1716-mediated oncolysis with gene transfer and targeted radiotherapy. Med. Chem.1(5), 423–429 (2005).
   PubMed Web of Science ®Google Scholar
• Shah AC, Benos D, Gillespie GY, Markert JM. Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas. J. Neurooncol.65(3), 203–226 (2003).
   PubMed Web of Science ®Google Scholar
• Kramm CM, Chase M, Herrlinger U et al. Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Hum. Gene Ther.8(17), 2057–2068 (1997).
   PubMed Web of Science ®Google Scholar
• Markert JM, Gillespie GY, Weichselbaum RR, Roizman B, Whitley RJ. Genetically engineered HSV in the treatment of glioma: a review. Rev. Med. Virol.10(1), 17–30 (2000).
   PubMed Web of Science ®Google Scholar
• Huszthy PC, Goplen D, Thorsen F et al. Oncolytic herpes simplex virus type-1 therapy in a highly infiltrative animal model of human glioblastoma. Clin. Cancer Res.14(5), 1571–1580 (2008).
   PubMed Web of Science ®Google Scholar
• Dambach MJ, Trecki J, Martin N, Markovitz NS. Oncolytic viruses derived from the γ34.5-deleted herpes simplex virus recombinant R3616 encode a truncated UL3 protein. Mol. Ther.13(5), 891–898 (2006).
   PubMed Web of Science ®Google Scholar
• Liu BL, Robinson M, Han ZQ et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther.10(4), 292–303 (2003).
   PubMed Web of Science ®Google Scholar
• Todo T, Martuza RL, Rabkin SD, Johnson PA. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc. Natl Acad. Sci. USA98(11), 6396–6401 (2001).
   PubMed Web of Science ®Google Scholar
• Boviatsis EJ, Park JS, Sena-Esteves M et al. Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res.54(22), 5745–5751 (1994).
   PubMed Web of Science ®Google Scholar
• Kramm CM, Rainov NG, Sena-Esteves M et al. Long-term survival in a rodent model of disseminated brain tumors by combined intrathecal delivery of herpes vectors and ganciclovir treatment. Hum. Gene Ther.7(16), 1989–1994 (1996).
   PubMed Web of Science ®Google Scholar
• Tyminski E, Leroy S, Terada K et al. Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan. Cancer Res.65(15), 6850–6857 (2005).
   PubMed Web of Science ®Google Scholar
• Hellums EK, Markert JM, Parker JN et al. Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model. Neuro Oncol.7(3), 213–224 (2005).
   PubMed Web of Science ®Google Scholar
• Parker JN, Gillespie GY, Love CE, Randall S, Whitley RJ, Markert JM. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc. Natl Acad. Sci. USA97(5), 2208–2213 (2000).
   PubMed Web of Science ®Google Scholar
• Varghese S, Rabkin SD, Liu R, Nielsen PG, Ipe T, Martuza RL. Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers. Cancer Gene Ther.13(3), 253–265 (2006).
   PubMed Web of Science ®Google Scholar
• Yang CT, Lin YC, Lin CL et al. Oncolytic herpesvirus with secretable angiostatic proteins in the treatment of human lung cancer cells. Anticancer Res25(3B), 2049–2054 (2005).
   PubMed Web of Science ®Google Scholar
• Liu TC, Zhang T, Fukuhara H et al. Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy. Mol. Ther.14(6), 789–797 (2006).
   PubMed Web of Science ®Google Scholar
• Liu TC, Zhang T, Fukuhara H et al. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors. Clin. Cancer Res.12(22), 6791–6799 (2006).
   PubMed Web of Science ®Google Scholar
• Terada K, Wakimoto H, Tyminski E, Chiocca EA, Saeki Y. Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models. Gene Ther.13(8), 705–714 (2006).
   PubMed Web of Science ®Google Scholar
• Kuroda T, Martuza RL, Todo T, Rabkin SD. Flip-Flop HSV–BAC: bacterial artificial chromosome based system for rapid generation of recombinant herpes simplex virus vectors using two independent site-specific recombinases. BMC Biotechnol.6, 40 (2006).
   PubMed Web of Science ®Google Scholar
• Aghi M, Rabkin S, Martuza RL. Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. J. Natl Cancer Inst.98(1), 38–50 (2006).
   PubMed Web of Science ®Google Scholar
• Hardcastle J, Kurozumi K, Chiocca EA, Kaur B. Oncolytic viruses driven by tumor-specific promoters. Curr. Cancer Drug Targets7(2), 181–189 (2007).
   PubMed Web of Science ®Google Scholar
• Kambara H, Okano H, Chiocca EA, Saeki Y. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res.65(7), 2832–2839 (2005).
   PubMed Web of Science ®Google Scholar
• Dahlstrand J, Collins VP, Lendahl U. Expression of the class VI intermediate filament nestin in human central nervous system tumors. Cancer Res.52(19), 5334–5341 (1992).
   PubMed Web of Science ®Google Scholar
• Dell’Albani P. Stem cell markers in gliomas. Neurochem. Res.33(12), 2407–2415 (2008).
   PubMed Web of Science ®Google Scholar
• Yao F, Schaffer PA. An activity specified by the osteosarcoma line U2OS can substitute functionally for ICP0, a major regulatory protein of herpes simplex virus type 1. J. Virol.69(10), 6249–6258 (1995).
   PubMed Web of Science ®Google Scholar
• Hummel JL, Safroneeva E, Mossman KL. The role of ICP0-Null HSV-1 and interferon signaling defects in the effective treatment of breast adenocarcinoma. Mol. Ther.12(6), 1101–1110 (2005).
   PubMed Web of Science ®Google Scholar
• Jordan R, Pepe J, Schaffer PA. Characterization of a nerve growth factor-inducible cellular activity that enhances herpes simplex virus type 1 gene expression and replication of an ICP0 null mutant in cells of neural lineage. J. Virol.72(7), 5373–5382 (1998).
   PubMed Web of Science ®Google Scholar
• Cai W, Astor TL, Liptak LM, Cho C, Coen DM, Schaffer PA. The herpes simplex virus type 1 regulatory protein ICP0 enhances virus replication during acute infection and reactivation from latency. J. Virol.67(12), 7501–7512 (1993).
   PubMed Web of Science ®Google Scholar
• Oehmig A, Fraefel C, Breakefield XO. Update on herpes virus amplicon vectors. Mol. Ther.10(4), 630–643 (2004).
   PubMed Web of Science ®Google Scholar
• Reinblatt M, Pin RH, Bowers WJ, Federoff HJ, Fong Y. Herpes simplex virus amplicon delivery of a hypoxia-inducible soluble vascular endothelial growth factor receptor (sFlk-1) inhibits angiogenesis and tumor growth in pancreatic adenocarcinoma. Ann. Surg. Oncol.12(12), 1025–1036 (2005).
   PubMed Web of Science ®Google Scholar
• Ho IA, Hui KM, Lam PY. Glioma-specific and cell cycle-regulated herpes simplex virus type 1 amplicon viral vector. Hum. Gene Ther.15(5), 495–508 (2004).
   PubMed Web of Science ®Google Scholar
• Epstein AL. HSV-1-based amplicon vectors: design and applications. Gene Ther.12(Suppl. 1), S154–S158 (2005).
   Google Scholar
• Epstein AL, Marconi P, Argnani R, Manservigi R. HSV-1-derived recombinant and amplicon vectors for gene transfer and gene therapy. Curr. Gene Ther.5(5), 445–458 (2005).
   PubMed Web of Science ®Google Scholar
• Cuchet D, Potel C, Thomas J, Epstein AL. HSV-1 amplicon vectors: a promising and versatile tool for gene delivery. Expert Opin. Biol. Ther.7(7), 975–995 (2007).
   PubMed Web of Science ®Google Scholar
• Inoue R, Moghaddam KA, Ranasinghe M, Saeki Y, Chiocca EA, Wade-Martins R. Infectious delivery of the 132 kb CDKN2A/CDKN2B genomic DNA region results in correctly spliced gene expression and growth suppression in glioma cells. Gene Ther.11(15), 1195–1204 (2004).
   PubMed Web of Science ®Google Scholar
• Barzilai A, Zivony-Elbom I, Sarid R, Noah E, Frenkel N. The herpes simplex virus type 1 vhs-UL41 gene secures viral replication by temporarily evading apoptotic cellular response to infection: vhs-UL41 activity might require interactions with elements of cellular mRNA degradation machinery. J. Virol.80(1), 505–513 (2006).
   PubMed Web of Science ®Google Scholar
• Saydam O, Glauser DL, Heid I et al. Herpes simplex virus 1 amplicon vector-mediated siRNA targeting epidermal growth factor receptor inhibits growth of human glioma cells in vivo. Mol. Ther.12(5), 803–812 (2005).
   PubMed Web of Science ®Google Scholar
• Santos K, Duke CM, Dewhurst S. Amplicons as vaccine vectors. Curr. Gene Ther.6(3), 383–392 (2006).
   PubMed Web of Science ®Google Scholar
• Lawler SE, Peruzzi PP, Chiocca EA. Genetic strategies for brain tumor therapy. Cancer Gene Ther.13(3), 225–233 (2006).
   PubMed Web of Science ®Google Scholar
• Schmidek HH, Nielsen SL, Schiller AL, Messer J. Morphological studies of rat brain tumors induced by N-nitrosomethylurea. J. Neurosurg.34(3), 335–340 (1971).
   PubMed Web of Science ®Google Scholar
• Fomchenko EI, Holland EC. Mouse models of brain tumors and their applications in preclinical trials. Clin. Cancer Res.12(18), 5288–5297 (2006).
   PubMed Web of Science ®Google Scholar
• Barth RF. Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas. J. Neurooncol.36(1), 91–102 (1998).
   PubMed Web of Science ®Google Scholar
• Shapiro WR, Basler GA, Chernik NL, Posner JB. Human brain tumor transplantation into nude mice. J. Natl Cancer Inst.62(3), 447–453 (1979).
   PubMed Web of Science ®Google Scholar
• Finkelstein SD, Black P, Nowak TP, Hand CM, Christensen S, Finch PW. Histological characteristics and expression of acidic and basic fibroblast growth factor genes in intracerebral xenogeneic transplants of human glioma cells. Neurosurgery34(1), 136–143 (1994).
   PubMed Web of Science ®Google Scholar
• Bao S, Wu Q, Sathornsumetee S et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res.66(16), 7843–7848 (2006).
   PubMed Web of Science ®Google Scholar
• Holland EC. Mouse models of human cancer as tools in drug development. Cancer Cell6(3), 197–198 (2004).
   PubMed Web of Science ®Google Scholar
• Uhrbom L, Hesselager G, Nister M, Westermark B. Induction of brain tumors in mice using a recombinant platelet-derived growth factor B-chain retrovirus. Cancer Res.58(23), 5275–5279 (1998).
   PubMed Web of Science ®Google Scholar
• Sakariassen PO, Prestegarden L, Wang J et al. Angiogenesis-independent tumor growth mediated by stem-like cancer cells. Proc. Natl Acad. Sci. USA103(44), 16466–16471 (2006).
   PubMed Web of Science ®Google Scholar
• Engebraaten O, Hjortland GO, Hirschberg H, Fodstad O. Growth of precultured human glioma specimens in nude rat brain. J. Neurosurg.90(1), 125–132 (1999).
   PubMed Web of Science ®Google Scholar
• Bjerkvig R, Tonnesen A, Laerum OD, Backlund EO. Multicellular tumor spheroids from human gliomas maintained in organ culture. J. Neurosurg.72(3), 463–475 (1990).
   PubMed Web of Science ®Google Scholar
• Chiocca EA. The host response to cancer virotherapy. Curr. Opin. Mol. Ther.10(1), 38–45 (2008).
   PubMedGoogle Scholar
• Corey L, Spear PG. Infections with herpes simplex viruses (2). N. Engl. J. Med.314(12), 749–757 (1986).
   PubMed Web of Science ®Google Scholar
• Corey L, Spear PG. Infections with herpes simplex viruses (1). N. Engl. J. Med.314(11), 686–691 (1986).
   PubMed Web of Science ®Google Scholar
• Herrlinger U, Kramm CM, Aboody-Guterman KS et al. Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector. Gene Ther.5(6), 809–819 (1998).
   PubMed Web of Science ®Google Scholar
• Ikeda K, Wakimoto H, Ichikawa T et al. Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. J. Virol.74(10), 4765–4775 (2000).
   PubMed Web of Science ®Google Scholar
• Mohr I. Neutralizing innate host defenses to control viral translation in HSV-1 infected cells. Int. Rev. Immunol.23(1–2), 199–220 (2004).
   PubMed Web of Science ®Google Scholar
• Goody RJ, Beckham JD, Rubtsova K, Tyler KL. JAK–STAT signaling pathways are activated in the brain following reovirus infection. J. Neurovirol.13(4), 373–383 (2007).
   PubMed Web of Science ®Google Scholar
• Otsuki A, Patel A, Kasai K et al. Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses. Mol. Ther.16(9), 1546–1555 (2008).
   PubMed Web of Science ®Google Scholar
• McKee TD, Grandi P, Mok W et al. Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res.66(5), 2509–2513 (2006).
   PubMed Web of Science ®Google Scholar
• Hay JG. The potential impact of hypoxia on the success of oncolytic virotherapy. Curr. Opin. Mol. Ther.7(4), 353–358 (2005).
   PubMed Web of Science ®Google Scholar
• Pipiya T, Sauthoff H, Huang YQ et al. Hypoxia reduces adenoviral replication in cancer cells by downregulation of viral protein expression. Gene Ther.12(11), 911–917 (2005).
   PubMed Web of Science ®Google Scholar
• Breitbach CJ, Paterson JM, Lemay CG et al. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol. Ther.15(9), 1686–1693 (2007).
   PubMed Web of Science ®Google Scholar
• Fulci G, Breymann L, Gianni D et al. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc. Natl Acad. Sci. USA103(34), 12873–12878 (2006).
   PubMed Web of Science ®Google Scholar
• Kambara H, Saeki Y, Chiocca EA. Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus. Cancer Res.65(24), 11255–11258 (2005).
   PubMed Web of Science ®Google Scholar
• Farrell CJ, Zaupa C, Barnard Z et al. Combination immunotherapy for tumors via sequential intratumoral injections of oncolytic herpes simplex virus 1 and immature dendritic cells. Clin. Cancer Res.14(23), 7711–7716 (2008).
   PubMed Web of Science ®Google Scholar
• Toda M, Rabkin SD, Kojima H, Martuza RL. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum. Gene Ther.10(3), 385–393 (1999).
   PubMed Web of Science ®Google Scholar
• Todo T, Martuza RL, Dallman MJ, Rabkin SD. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity. Cancer Res.61(1), 153–161 (2001).
   PubMed Web of Science ®Google Scholar
• Todo T, Rabkin SD, Chahlavi A, Martuza RL. Corticosteroid administration does not affect viral oncolytic activity, but inhibits antitumor immunity in replication-competent herpes simplex virus tumor therapy. Hum. Gene Ther.10(17), 2869–2878 (1999).
   PubMed Web of Science ®Google Scholar
• Todo T, Rabkin SD, Sundaresan P et al. Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum. Gene Ther.10(17), 2741–2755 (1999).
   PubMed Web of Science ®Google Scholar
• Benencia F, Courreges MC, Conejo-Garcia JR et al. HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer. Mol. Ther.12(5), 789–802 (2005).
   PubMed Web of Science ®Google Scholar
• Benencia F, Courreges MC, Conejo-Garcia JR, Mohammed-Hadley A, Coukos G. Direct vaccination with tumor cells killed with ICP4-deficient HSVd120 elicits effective antitumor immunity. Cancer Biol. Ther.5(7), 867–874 (2006).
   PubMed Web of Science ®Google Scholar
• Miller CG, Fraser NW. Role of the immune response during neuro-attenuated herpes simplex virus-mediated tumor destruction in a murine intracranial melanoma model. Cancer Res.60(20), 5714–5722 (2000).
   PubMed Web of Science ®Google Scholar
• Kondraganti S, Mohanam S, Chintala SK et al. Selective suppression of matrix metalloproteinase-9 in human glioblastoma cells by antisense gene transfer impairs glioblastoma cell invasion. Cancer Res.60(24), 6851–6855 (2000).
   PubMed Web of Science ®Google Scholar
• Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T. Regulation of matrix metalloproteinases: an overview. Mol. Cell. Biochem.253(1–2), 269–285 (2003).
   PubMed Web of Science ®Google Scholar
• Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J. Clin. Oncol.18(5), 1135–1149 (2000).
   PubMed Web of Science ®Google Scholar
• Choe G, Park JK, Jouben-Steele L et al. Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype. Clin. Cancer Res.8(9), 2894–2901 (2002).
   PubMed Web of Science ®Google Scholar
• Shen Y, Nemunaitis J. Herpes simplex virus 1 (HSV-1) for cancer treatment. Cancer Gene Ther.13, 975–992 (2006).
   PubMed Web of Science ®Google Scholar